For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...
Mwyngil Therapeutics, a clinical-stage biopharmaceutical company focused on immunometabolic and neuroinflammatory diseases, today announced the initiation of a Phase 1 clinical study of BT-409, a ...
Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced the successful completion of an ...
AppFactor, the agentic orchestration platform that delivers autonomous maintenance for enterprise software, announced a $4 ...
Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary ...
BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug ...
Researchers developed a mouse model of multiple sclerosis that captures the features of progression independent of relapse ...
After up to three years on GA Depot, most people with PPMS have not experienced any disability progression, according to new ...
A collaborative team of researchers and students from Wayne State University's Eugene Applebaum College of Pharmacy and ...
Generic comorbidity measures may not reflect the unique clinical profile of people with MS, hitting a predictive ceiling.
A study from UCSF shows a previously unknown connection between the Epstein-Barr virus, known to play a role in MS, and an ...
Specialists in multiple sclerosis will gather in San Diego for ACTRIMS Forum 2026, Feb. 5-7, where the theme will be “MS at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results